These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482 [TBL] [Abstract][Full Text] [Related]
26. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. Callaway CW; Wing LL; Geyer MA J Pharmacol Exp Ther; 1990 Aug; 254(2):456-64. PubMed ID: 1974635 [TBL] [Abstract][Full Text] [Related]
27. Effects of amphetamine analogs on central nervous system neuropeptide systems. Hanson GR; Sonsalla P; Letter A; Merchant KM; Johnson M; Bush L; Gibb JW NIDA Res Monogr; 1989; 94():259-69. PubMed ID: 2481828 [No Abstract] [Full Text] [Related]
28. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. Nash JF; Meltzer HY; Gudelsky GA J Pharmacol Exp Ther; 1988 Jun; 245(3):873-9. PubMed ID: 2898523 [TBL] [Abstract][Full Text] [Related]
29. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain. Gibb JW; Stone DM; Stahl DC; Hanson GR NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619 [TBL] [Abstract][Full Text] [Related]
30. MDMA. The dark side of ecstasy. Hayner GN; McKinney H J Psychoactive Drugs; 1986; 18(4):341-7. PubMed ID: 2880949 [No Abstract] [Full Text] [Related]
31. The psychological and physiological effects of MDMA on normal volunteers. Downing J J Psychoactive Drugs; 1986; 18(4):335-40. PubMed ID: 2880948 [TBL] [Abstract][Full Text] [Related]
32. Some considerations on the prevalence of MDMA use. Newmeyer JA J Psychoactive Drugs; 1986; 18(4):361-2. PubMed ID: 2880952 [No Abstract] [Full Text] [Related]
33. Controls over the manufacture of MDMA. Holsten DW; Schieser DW J Psychoactive Drugs; 1986; 18(4):371-2. PubMed ID: 2880954 [No Abstract] [Full Text] [Related]
34. Responses to i.v. L-tryptophan in MDMA users. Price LH; Ricaurte GA; Krystal JH; Heninger GR NIDA Res Monogr; 1989; 95():421-2. PubMed ID: 2577044 [No Abstract] [Full Text] [Related]
35. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). Brown C; Osterloh J JAMA; 1987 Aug; 258(6):780-1. PubMed ID: 2886672 [No Abstract] [Full Text] [Related]
36. Structure-activity relationships of MDMA-like substances. Nichols DE; Oberlender R NIDA Res Monogr; 1989; 94():1-29. PubMed ID: 2575223 [No Abstract] [Full Text] [Related]
39. Advantages and disadvantages of a rapid method to train drug discrimination. Schechter MD Pharmacol Biochem Behav; 1988 Sep; 31(1):239-42. PubMed ID: 2908064 [TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Nichols DE; Oberlender R Ann N Y Acad Sci; 1990; 600():613-23; discussion 623-5. PubMed ID: 1979214 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]